Alan J. Kivitz, MD: Phase 2b Data on TAK-279 for Psoriatic A

During this interview, Dr. Kivitz explained the background and key findings of his team’s research on TAK-279, a selective oral TYK2 inhibitor.

Related Keywords

California , United States , San Diego , Alanj Kivitz , , Clinical Research , American College Of Rheumatology , Altoona Center , Altoona Arthritis Osteoporosis Center , Altoona Arthritis , American College , Racr , Psoriatic Arthritis , Tak 279 , Phase 2b ,